MERSANA THERAPEUTICS INC (MRSN) Stock Price, Quote, News and Overview
NASDAQ:MRSN - Nasdaq - US59045L1061 - Common Stock - Currency: USD
MRSN Quote, Performance and Key Statistics
0.528
-0.03 (-5.21%)
The current stock price of MRSN is 0.528 USD. In the past month the price increased by 0.09%. In the past year, price decreased by -86.07%.
MRSN Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 19.85 | 354.98B | ||
| AMGN | AMGEN INC | 15.03 | 159.99B | ||
| GILD | GILEAD SCIENCES INC | 23.87 | 137.10B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 1656.31 | 123.40B | ||
| REGN | REGENERON PHARMACEUTICALS | 15.25 | 76.09B | ||
| ARGX | ARGENX SE - ADR | N/A | 39.34B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 32.37B | ||
| BNTX | BIONTECH SE-ADR | N/A | 28.26B | ||
| ONC | BEIGENE LTD-ADR | N/A | 26.06B | ||
| NTRA | NATERA INC | N/A | 22.20B | ||
| BIIB | BIOGEN INC | 8.32 | 19.98B | ||
| SMMT | SUMMIT THERAPEUTICS INC | N/A | 17.01B |
Related stock screener links
About MRSN
Company Profile
Mersana Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of antibody-drug conjugates that offer clinical benefit for cancer patients. The company is headquartered in Cambridge, Massachusetts and currently employs 123 full-time employees. The company went IPO on 2017-06-28. The company has developed two proprietary and differentiated ADC platforms: Dolasynthen and Immunosynthen. Dolasynthen is its cytotoxic ADC platform that is designed to generate site-specific, homogeneous ADCs. Immunosynthen is its proprietary stimulator of interferon genes (STING)-agonist platform that is designed to generate systemically administered ADCs that locally activate STING signaling in both antigen-expressing tumor cells and in tumor-resident immune cells. The firm's pipeline also includes XMT-1660, a Dolasynthen ADC targeting B7-H4 in a Phase I clinical trial, and XMT-2056, an Immunosynthen ADC targeting a novel epitope of human epidermal growth factor receptor 2 (HER2), in addition to other earlier-stage assets.
Company Info
MERSANA THERAPEUTICS INC
840 Memorial Dr
Cambridge MASSACHUSETTS 02139 US
CEO: Anna Protopapas
Employees: 123
Company Website: https://www.mersana.com/
Investor Relations: https://ir.mersana.com/
Phone: 16174980020
MERSANA THERAPEUTICS INC / MRSN FAQ
What is the stock price of MERSANA THERAPEUTICS INC today?
The current stock price of MRSN is 0.528 USD. The price decreased by -5.21% in the last trading session.
What is the ticker symbol for MERSANA THERAPEUTICS INC stock?
The exchange symbol of MERSANA THERAPEUTICS INC is MRSN and it is listed on the Nasdaq exchange.
On which exchange is MRSN stock listed?
MRSN stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for MERSANA THERAPEUTICS INC stock?
16 analysts have analysed MRSN and the average price target is 5.48 USD. This implies a price increase of 938.35% is expected in the next year compared to the current price of 0.528. Check the MERSANA THERAPEUTICS INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is MERSANA THERAPEUTICS INC worth?
MERSANA THERAPEUTICS INC (MRSN) has a market capitalization of 61.06M USD. This makes MRSN a Micro Cap stock.
How many employees does MERSANA THERAPEUTICS INC have?
MERSANA THERAPEUTICS INC (MRSN) currently has 123 employees.
Is MERSANA THERAPEUTICS INC (MRSN) expected to grow?
The Revenue of MERSANA THERAPEUTICS INC (MRSN) is expected to decline by -22.53% in the next year. Check the estimates tab for more information on the MRSN EPS, Sales, EBIT and EBITDA future analyst estimates.
Should I buy MERSANA THERAPEUTICS INC (MRSN) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of MRSN, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of MRSN, evaluating the profitability, health, valuation and growth aspects
- MERSANA THERAPEUTICS INC (MRSN) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- MERSANA THERAPEUTICS INC (MRSN) Sales and EPS estimates to see what analysts future expectations are.
- MERSANA THERAPEUTICS INC (MRSN) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- MERSANA THERAPEUTICS INC (MRSN) Insider and Institutional Ownership to learn about the owners and their transactions.
- MERSANA THERAPEUTICS INC (MRSN) Stock Chart to make your own analysis
- MERSANA THERAPEUTICS INC (MRSN) Latest news and press-releases to stay up to date.
Does MERSANA THERAPEUTICS INC (MRSN) stock pay dividends?
MRSN does not pay a dividend.
When does MERSANA THERAPEUTICS INC (MRSN) report earnings?
MERSANA THERAPEUTICS INC (MRSN) will report earnings on 2025-02-26, after the market close.
What is the Price/Earnings (PE) ratio of MERSANA THERAPEUTICS INC (MRSN)?
MERSANA THERAPEUTICS INC (MRSN) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.61).
What is the Short Interest ratio of MERSANA THERAPEUTICS INC (MRSN) stock?
The outstanding short interest for MERSANA THERAPEUTICS INC (MRSN) is 8.32% of its float. Check the ownership tab for more information on the MRSN short interest.
MRSN Technical Analysis
ChartMill assigns a technical rating of 1 / 10 to MRSN. When comparing the yearly performance of all stocks, MRSN is a bad performer in the overall market: 99.25% of all stocks are doing better.
MRSN Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to MRSN. MRSN has a bad profitability rating. Also its financial health evaluation is rather negative.
MRSN Financial Highlights
Over the last trailing twelve months MRSN reported a non-GAAP Earnings per Share(EPS) of -0.61. The EPS increased by 64.12% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -44.02% | ||
| ROE | -7113.35% | ||
| Debt/Equity | 13.35 |
MRSN Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 85% to MRSN. The Buy consensus is the average rating of analysts ratings from 16 analysts.
For the next year, analysts expect an EPS growth of 56.25% and a revenue growth -22.53% for MRSN